The researchers highlight tracers such as [18 F]F-0502B, [18 F]C05-05, and [18 F]ACI-12589, which have demonstrated encouraging results in distinguishing patients with synucleinopathies from ...

The abnormal accumulation of α-synuclein protein is a defining pathological feature of several neurodegenerative conditions collectively known as synucleinopathies, including Parkinson's disease ...

Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.

disordered regions that extend from the fibril core—in prion-like pathological transmission in synucleinopathies. Their work was published in Neuron on April 10. The researchers first conducted serial ...

DLB and PD are both so-called synucleinopathies, diseases that are characterised by mutations in the SNCA gene coding for alpha-synuclein, leading to the production of misfolded, toxic forms of ...

Researchers from Aarhus University and Synuca Therapeutics recently presented a novel drug-like small-molecule inhibitor of sarco/endoplasmic reticulum calcium ATPase (SERCA), SYN-4569, with superior ...

Get Instant Summarized Text (Gist) Recent advances in PET tracers enable in vivo visualization of α-synuclein aggregates, a hallmark of synucleinopathies such as Parkinson’s disease, multiple ...

The abnormal accumulation of α-synuclein protein is a defining pathological feature of several neurodegenerative conditions collectively known as synucleinopathies, including Parkinson's disease ...

The abnormal accumulation of α-synuclein protein is a defining pathological feature of several neurodegenerative conditions collectively known as synucleinopathies, including Parkinson's disease (PD), ...